



*PrDx an AI solution to address
a strong need for better cancer biomarker*


STEPHAN THORGRIMSEN PHD, MBA, CEO



IMMUNITRACK

Immune check-point blockade (ICB) are therapeutics that have revolutionised the way we treat cancer patients today

ICB stimulates the immune system in attacking cancer.



Problem:

only **1 in 5** patients
treated respond.



Why?

Current FDA approved
biomarkers lack accuracy.



UNMET NEED:
**Better Cancer
Biomarker**





IMMUNITRACK

UNMET NEED: Better Cancer Biomarker


Health consequences

Unnecessary **toxic**
treatment to patients.




Economic consequences

Huge costs to
healthcare systems globally



IMMUNITRACK

Better Cancer Biomarker




PRECISION MEDICINE

Tumour neo-epitope load

is a more accurate biomarker of patient clinical outcome to ICB.



IMMUNITRACK



Neo-epitope = cancer mutation presented by HLA receptors

How can we profile a tumor neo-epitope presentation by tumour?

Current solutions:



In vitro biochemical assay:
Expensive and lengthy
Not scalable



Neo-Epitope Prediction Software
Lack of accuracy

Solution?

PrDx™




Our Solution:

Use *PrDx*™, a fast, scalable and reliable AI solution to:

profile patient specific cancer neo-epitope load

How?



Hospitals provide DNA and RNA sequencing result from patient tumour.



PrDx™ lists and ranks likely neo-epitopes.



Results are provided for decision makers to:
Select likely responders to ICB.



IMMUNITRACK

PrDx™

Developed on
most advanced AI
and trained on
unique data




IMMUNITRACK




AI model

Feedforward neural network



Unique data

NeoScreen® platform:
HLA/epitope binding
biochemical assay*




PrDx™

Prediction software



*NeoScreen® commercialised since 2016.



PrDx™ outperforms other
software AUC score


PrDx™

VALUE
PROPOSITION

REDUCED COST

TIME TO MARKET

INCREASED SAFETY



Minimising
ineffective
treatment and
toxic side-effects



Decrease ICB
cost to health
care systems



Ultimately
ensure better
treatments to
reach patients



IMMUNITRACK

PrDx™

FINANCIAL PROJECTIONS

Sales projections

Sales of PrDx reports
€200/patient report



IMMUNITRACK



	2022	2023	2024	2025	2026
Annual revenue K€	0	0	6,700	26,800	67,000
Annual cost K€	1,922	2,915	3,261	6,449	8,250
Retained annual earning K€	-1,922	-2,915	3,439	20,351	58,750
FTE created	4	9	7	25	25

Market Penetration – precision medicine			0,5%	2%	5%
---	--	--	------	----	----

TARGETING A GROWING MARKET

BY
2026:

€ 26.7 Bn
Cancer Biomarker
CAGR 12%

€ 1.34 Bn
TAM in 2026

PrDx™

BY
2026:

K€ 100,500
Total revenue

K€ 22,797
Total costs

K€ 77,703
Total retained earning

70
Total FTE

PrDx™

**Collaboration with
world leading
research groups in
cancer biomarker
research**



Rigshospitalet



Ulrik Lassen, MD, PhD

Head of Department of Oncology
Professor of clinical Oncology
Head of Phase I unit.

SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER

**BLOOMBERG~KIMMEL INSTITUTE
FOR CANCER IMMUNOTHERAPY**



Drew Pardoll, MD, PhD

Co-Director Division of Immunology
and Hematopoiesis



IMMUNITRACK

PrDx™

TEAM
UNIQUE
KNOWLEDGE &
CAPABILITIES



IMMUNITRACK



Sune Justesen

PhD CSO and co-founder

+15 years experience with HLA biochemical assays.



Stephan Thorgrimsen

PhD, CEO and co-founder

MBA (2nd startup)



Frederik Bagger

PhD bioinformatics.

Associate professor at Copenhagen University

10 years of experience in algorithm development and data training



Robin Campbell

PhD, Board Director

Marketing strategy

30 years of experience in life science marketing



**Laboratory production/
data analysis:**
5 FTE

**Software Interface
development:**
1 consultant

**PrDx algorithm
development**
+1 FTE

Business development:
2 consultant
SAAS, biotech licens



- 1) PrDx optimization
- 2) Validation by analysis of clinical data
- 3) Regulatory compliance and IP strategy.
- 4) BD and market intelligence.

Contact details

Stephan Thorgrimsen

Email: sthor@immunitrack.com

Tlf: 004528682159

Homepage: www.immunitrack.com



IMMUNITRACK



IMMUNITRACK

THANK YOU!